Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
Agenus Inc. announces the release of its fourth quarter and year-end 2023 financial results on March 14, 2024. The company, known for its novel immunological agents to treat cancers, will host a conference call and webcast to discuss the results and provide a corporate update.
02/29/2024 - 07:30 AM
Conference Call on Thursday, March 14, 2024 at 8:30 a.m. ET
LEXINGTON, Mass. --(BUSINESS WIRE)--
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call:
To access dial-in numbers, please register here .
A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/678927380 .
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio . Information that may be important to investors will be routinely posted on our website and social media channels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229561817/en/
Investors
investor@agenusbio.com
Media
communications@agenusbio.com
Source: Agenus Inc.
When will Agenus release its fourth quarter and year-end 2023 financial results?
Agenus will release its fourth quarter and year-end 2023 financial results on Thursday, March 14, 2024.
What does Agenus specialize in?
Agenus specializes in discovering and developing novel immunological agents to treat various cancers.
What time will the conference call and webcast take place on March 14, 2024?
The conference call and webcast will take place at 8:30 a.m. ET on March 14, 2024.
Where can I access the live webcast and replay of the conference call?
The live webcast and replay of the conference call can be accessed on Agenus' website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/678927380.
AGEN Rankings
#5098 Ranked by Stock Gains
AGEN Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Lexington
About AGEN
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
